Market open
Lyell Immunopharma/$LYEL
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Lyell Immunopharma
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
Ticker
$LYEL
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
224
Website
LYEL Metrics
BasicAdvanced
$171M
Market cap
-
P/E ratio
-$0.80
EPS
-0.48
Beta
-
Dividend rate
Price and volume
Market cap
$171M
Beta
-0.48
52-week high
$3.26
52-week low
$0.58
Average daily volume
1.5M
Financial strength
Current ratio
13.429
Quick ratio
13.146
Long term debt to equity
9.693
Total debt to equity
11.037
Management effectiveness
Return on assets (TTM)
-19.12%
Return on equity (TTM)
-33.22%
Valuation
Price to revenue (TTM)
2,481.377
Price to book
0.3
Price to tangible book (TTM)
0.3
Price to free cash flow (TTM)
-0.999
Growth
Revenue change (TTM)
-99.87%
Earnings per share change (TTM)
5.39%
3-year revenue growth (CAGR)
-81.62%
3-year earnings per share growth (CAGR)
-32.39%
What the Analysts think about LYEL
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Lyell Immunopharma stock.
LYEL Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
LYEL Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
LYEL News
AllArticlesVideos
Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting
GlobeNewsWire·2 weeks ago
Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting
GlobeNewsWire·2 months ago
Lyell Immunopharma Completes Acquisition of ImmPACT Bio
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Lyell Immunopharma stock?
Lyell Immunopharma (LYEL) has a market cap of $171M as of December 26, 2024.
What is the P/E ratio for Lyell Immunopharma stock?
The price to earnings (P/E) ratio for Lyell Immunopharma (LYEL) stock is 0 as of December 26, 2024.
Does Lyell Immunopharma stock pay dividends?
No, Lyell Immunopharma (LYEL) stock does not pay dividends to its shareholders as of December 26, 2024.
When is the next Lyell Immunopharma dividend payment date?
Lyell Immunopharma (LYEL) stock does not pay dividends to its shareholders.
What is the beta indicator for Lyell Immunopharma?
Lyell Immunopharma (LYEL) has a beta rating of -0.48. This means that it has an inverse relation to market volatility.